BJA Advance Access originally published online on December 10, 2004
British Journal of Anaesthesia 2005 94(3):271-278; doi:10.1093/bja/aei044
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR |
Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage
Departments of 1 Anaesthesia and 2 Haematology, Southampton University Hospitals, Southampton, UK
* Corresponding author: Southampton University Hospitals, Tremona Road, Southampton SO16 6YD, UK. E-mail: ravi.gill{at}suht.swest.nhs.uk
Background. The transfusion of allogeneic red blood cells and allogeneic coagulation products is associated with risk to the patient and the depletion of an increasingly scarce resource. This prospective, randomized, double-blind, placebo-controlled trial investigated practices to avoid transfusion in patients undergoing first-time cardiac surgery.
Methods. Patients were randomized to one of three treatment groups: an aprotinin group, a tranexamic acid group, and a control group receiving normal saline. Intra-operative cell salvage was used for all patients. The primary outcomes were the number of patients exposed to allogeneic red blood cells, allogeneic coagulation products or any allogeneic transfusion (allogeneic red blood cells and/or allogeneic coagulation products).
Results. Patients were 2.5 times more likely to receive any allogeneic transfusion in the tranexamic group than in the aprotinin group (21 patients out of 60 compared with nine out of 60, respectively). The relative risk of any allogeneic transfusion comparing aprotinin with tranexamic acid was 0.43 (95% confidence interval 0.21–0.86; P=0.019). Patients in the control group were four times more likely to receive any allogeneic transfusion when compared with the aprotinin group (37 patients out of 60 compared with nine out of 60, respectively). The relative risk of any allogeneic transfusion comparing aprotinin with control was 0.24 (95% confidence interval 0.13–0.46; P<0.001).
Conclusions. When used in addition to intra-operative cell salvage, aprotinin is the most efficacious pharmacological therapy for reducing patient exposure to any allogeneic transfusion during first-time cardiac surgery.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Levrat, A. Gros, L. Rugeri, K. Inaba, B. Floccard, C. Negrier, and J.-S. David Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients Br. J. Anaesth., June 1, 2008; 100(6): 792 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Dietrich, A. Ebell, R. Busley, and A.-L. Boulesteix Aprotinin and Anaphylaxis: Analysis of 12,403 Exposures to Aprotinin in Cardiac Surgery Ann. Thorac. Surg., October 1, 2007; 84(4): 1144 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2801 - 2813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Warren, K. Mandal, V. Hadjianastassiou, L. Knowlton, S. Panesar, K. John, A. Darzi, and T. Athanasiou Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review Ann. Thorac. Surg., February 1, 2007; 83(2): 707 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Beattie and K. Karkouti Con: Aprotinin Has a Good Efficacy and Safety Profile Relative to Other Alternatives for Prevention of Bleeding in Cardiac Surgery Anesth. Analg., December 1, 2006; 103(6): 1360 - 1364. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ozier and S. Schlumberger Pharmacological approaches to reducing blood loss and transfusions in the surgical patient: [Approches pharmacologiques de reduction des pertes sanguines et des transfusions en chirurgie] Can J Anesth, June 1, 2006; 53(6_suppl): S21 - S29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Diprose, M. J. Herbertson, D. O'Shaughnessy, and R. S. Gill Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study Br. J. Anaesth., November 1, 2005; 95(5): 596 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Tempe Reducing allogeneic transfusion in cardiac surgery Br. J. Anaesth., August 1, 2005; 95(2): 277 - 278. [Full Text] [PDF]
|
|
E-letters:
Read all E-letters
- Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled tri
- Deepak K. Tempe
- British Journal of Anaesthesia, 30 Apr 2005 [Full text]
- In response to - Reducing allogenic transfusion in cardiac surgery: a randomized double-blind placeb
- Praveen Kumar Neema, et al.
- British Journal of Anaesthesia, 23 Sep 2005 [Full text]